Durable Remission after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Refractory Mycosis Fungoides: A Case Report
-
Mekni Sabrine
,
Ben Hammamia Hana
,
Noureddine Litaiem
,
Kanoun Rimmel Yosra
,
Torjemane Lamia
,
Belloumi Dorra
,
Ben Yaiche Insaf
,
Ouerghi Rihab
,
Turki Ines
,
Chaabane Anna
,
Ben Othman Tarek
,
Ben Abdeljelil Nour
Abstract
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL) and is characterized by a heterogeneous clinical course and variant stage involvement. Indolent disease is usually observed in its early stages. However, the treatment options for patients with advanced MF are limited and have poor outcomes. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for refractory cases. Here, we describe the case of a 34-year-old man who was diagnosed with MF at an advanced stage. Eight months before allo-HSCT, the patient received six courses of polychemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisolone, which were administered every three weeks. A partial response was obtained.
He underwent allo-HSCT after a myeloablative conditioning regimen and remained in complete remission (CR) for 26 months posttransplantation. Our findings confirm that allo-HSCT can be a curative option for refractory MF.
1. Kalay Yildizhan I, Sanli H, Akay BN, et al. Folliculotropic mycosis fungoides: Clinical characteristics, treatments, and long-term outcomes of 53 patients in a tertiary hospital. Dermatol Ther. 2020;33(4):e13585.
2. Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(1):193‑209.
3. Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol .2011;22(7):1608‑13.
4. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. [Internet]. [cité 20 févr 2024]. Disponible sur: https://reference.medscape.com/medline/abstract/19589488
5. Fatima S, Siddiqui S, Tariq MU, et al. Mycosis Fungoides: A Clinicopathological Study of 60 Cases from a Tertiary Care Center. Indian J Dermatol. 2020;65(2):123‑9.
6. Raghavan SS, Kim J. Histopathologic approach to epidermotropic lymphocytic infiltrates. Semin Cutan Med Surg. 2018;37(1):56‑60.
7. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713‑22.
8. Tarabadkar ES, Shinohara MM. Skin Directed Therapy in Cutaneous T-Cell Lymphoma. Front Oncol. 2019;9:260.
9. Gregoriou S, Rigopoulos D, Stamou C, et al. Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas. J Cutan Med Surg. 2013;17(1):52‑4.
10. Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41(7):597‑604.
11. Applewaite R, Scarisbrick J. Tre-P-20 - Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T-cell lymphoma at a tertiary care centre. Eur J Cancer. 1 oct 2021;156:S55.
12. Mori T, Shiratori S, Suzumiya J, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. Hematol Oncol. 2020;38(3):266‑71.
13. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730‑9.
14. Duarte RF, Boumendil A, Onida F, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347‑8.
15. Hosing C, Bassett R, Dabaja B, T et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490‑5.
16. de Masson A, Beylot-Barry M, Ram-Wolff C, et al. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet 2023;401(10392):1941‑50.
17. Goyal A, O’Leary D, Foss F. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis. Bone Marrow Transplant. 2024;59(1):41‑51.
18. Lechowicz MJ, Lazarus HM, Carreras J, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49(11):1360‑5.
19. Talpur R, Singh L, Daulat S, et al. Long term outcomes of 1263 patients with Mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051-60.
20. Chen Z, Lin Y, Qin Y, et al. Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China: A 12-Year Review. JAMA Dermatol. 2023; 159(10):1059‑67.
21. Shiratori S, Fujimoto K, Nishimura M, et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. Hematol Oncol. 2016;34(1):9‑16.
22. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2023:195:113343.
23. Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. OncoTargets Ther. 2019;12:1085‑94.
24. Stuver R, Geller S. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments. Front Immunol. 2023;14:1284045.
2. Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(1):193‑209.
3. Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol .2011;22(7):1608‑13.
4. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. [Internet]. [cité 20 févr 2024]. Disponible sur: https://reference.medscape.com/medline/abstract/19589488
5. Fatima S, Siddiqui S, Tariq MU, et al. Mycosis Fungoides: A Clinicopathological Study of 60 Cases from a Tertiary Care Center. Indian J Dermatol. 2020;65(2):123‑9.
6. Raghavan SS, Kim J. Histopathologic approach to epidermotropic lymphocytic infiltrates. Semin Cutan Med Surg. 2018;37(1):56‑60.
7. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713‑22.
8. Tarabadkar ES, Shinohara MM. Skin Directed Therapy in Cutaneous T-Cell Lymphoma. Front Oncol. 2019;9:260.
9. Gregoriou S, Rigopoulos D, Stamou C, et al. Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas. J Cutan Med Surg. 2013;17(1):52‑4.
10. Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41(7):597‑604.
11. Applewaite R, Scarisbrick J. Tre-P-20 - Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T-cell lymphoma at a tertiary care centre. Eur J Cancer. 1 oct 2021;156:S55.
12. Mori T, Shiratori S, Suzumiya J, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. Hematol Oncol. 2020;38(3):266‑71.
13. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730‑9.
14. Duarte RF, Boumendil A, Onida F, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347‑8.
15. Hosing C, Bassett R, Dabaja B, T et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490‑5.
16. de Masson A, Beylot-Barry M, Ram-Wolff C, et al. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. Lancet 2023;401(10392):1941‑50.
17. Goyal A, O’Leary D, Foss F. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis. Bone Marrow Transplant. 2024;59(1):41‑51.
18. Lechowicz MJ, Lazarus HM, Carreras J, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49(11):1360‑5.
19. Talpur R, Singh L, Daulat S, et al. Long term outcomes of 1263 patients with Mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051-60.
20. Chen Z, Lin Y, Qin Y, et al. Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China: A 12-Year Review. JAMA Dermatol. 2023; 159(10):1059‑67.
21. Shiratori S, Fujimoto K, Nishimura M, et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. Hematol Oncol. 2016;34(1):9‑16.
22. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2023:195:113343.
23. Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. OncoTargets Ther. 2019;12:1085‑94.
24. Stuver R, Geller S. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments. Front Immunol. 2023;14:1284045.
| Files | ||
| Issue | Vol 19 No 2 (2025) | |
| Section | Case Report(s) | |
| Keywords | ||
| Mycosis Fungoides; Allogeneic stem cell transplantation; Refractory | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Sabrine M, Hana B, Litaiem N, Yosra K, Lamia T, Dorra B, Insaf B, Rihab O, Ines T, Anna C, Tarek B, Nour B. Durable Remission after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Refractory Mycosis Fungoides: A Case Report. Int J Hematol Oncol Stem Cell Res. 2025;19(2):193-197.
